Exclusive Summary

• The innovator's patent has long expired, presenting zero IP barriers and enabling seamless market entry globally.
• With over 1.3 billion hypertension and heart failure patients worldwide, it acts as a chronic disease necessity with immense, recurring procurement demand.
• Listed on the WHO Essential Medicines and endorsed as first-line therapy by major guidelines, the 5mg/10mg dosages are gold standards for public tenders.
• Leveraging robust large-scale manufacturing and API-formulation cost advantages, Chinese suppliers highly empower distributors to aggressively win local public pricing bids.
• Equipped with internationally acceptable CTD dossiers and rigorous GMP compliance, guaranteeing a rapid regulatory approval and distribution process for overseas partners.